Logo image of PDSB

PDS BIOTECHNOLOGY CORP (PDSB) Stock Fundamental Analysis

NASDAQ:PDSB - Nasdaq - US70465T1079 - Common Stock - Currency: USD

1.19  -0.01 (-0.83%)

After market: 1.2199 +0.03 (+2.51%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PDSB. PDSB was compared to 551 industry peers in the Biotechnology industry. PDSB has a bad profitability rating. Also its financial health evaluation is rather negative. PDSB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PDSB had negative earnings in the past year.
In the past year PDSB has reported a negative cash flow from operations.
PDSB had negative earnings in each of the past 5 years.
PDSB had a negative operating cash flow in each of the past 5 years.
PDSB Yearly Net Income VS EBIT VS OCF VS FCFPDSB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -75.48%, PDSB is not doing good in the industry: 66.91% of the companies in the same industry are doing better.
PDSB has a Return On Equity of -158.73%. This is in the lower half of the industry: PDSB underperforms 64.00% of its industry peers.
Industry RankSector Rank
ROA -75.48%
ROE -158.73%
ROIC N/A
ROA(3y)-69.42%
ROA(5y)-56.3%
ROE(3y)-151.69%
ROE(5y)-107.33%
ROIC(3y)N/A
ROIC(5y)N/A
PDSB Yearly ROA, ROE, ROICPDSB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PDSB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PDSB Yearly Profit, Operating, Gross MarginsPDSB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for PDSB has been increased compared to 1 year ago.
PDSB has more shares outstanding than it did 5 years ago.
PDSB has a worse debt/assets ratio than last year.
PDSB Yearly Shares OutstandingPDSB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
PDSB Yearly Total Debt VS Total AssetsPDSB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PDSB has an Altman-Z score of -6.20. This is a bad value and indicates that PDSB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PDSB (-6.20) is worse than 65.09% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that PDSB is not too dependend on debt financing.
PDSB has a worse Debt to Equity ratio (0.29) than 72.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -6.2
ROIC/WACCN/A
WACCN/A
PDSB Yearly LT Debt VS Equity VS FCFPDSB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

PDSB has a Current Ratio of 2.33. This indicates that PDSB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.33, PDSB is not doing good in the industry: 72.55% of the companies in the same industry are doing better.
A Quick Ratio of 2.33 indicates that PDSB has no problem at all paying its short term obligations.
The Quick ratio of PDSB (2.33) is worse than 70.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.33
PDSB Yearly Current Assets VS Current LiabilitesPDSB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.20% over the past year.
EPS 1Y (TTM)25.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.79% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.86%
EPS Next 2Y3.88%
EPS Next 3Y3.29%
EPS Next 5Y17.79%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PDSB Yearly Revenue VS EstimatesPDSB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M
PDSB Yearly EPS VS EstimatesPDSB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PDSB. In the last year negative earnings were reported.
Also next year PDSB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PDSB Price Earnings VS Forward Price EarningsPDSB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PDSB Per share dataPDSB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.88%
EPS Next 3Y3.29%

More info and screens

0

5. Dividend

5.1 Amount

PDSB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (8/15/2025, 8:00:00 PM)

After market: 1.2199 +0.03 (+2.51%)

1.19

-0.01 (-0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners18.09%
Inst Owner Change-0.1%
Ins Owners2.11%
Ins Owner Change1.81%
Market Cap54.39M
Analysts82.22
Price Target7.65 (542.86%)
Short Float %5.52%
Short Ratio3.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.06%
Min EPS beat(2)16.54%
Max EPS beat(2)25.59%
EPS beat(4)3
Avg EPS beat(4)18.31%
Min EPS beat(4)-2.15%
Max EPS beat(4)33.29%
EPS beat(8)6
Avg EPS beat(8)16.67%
EPS beat(12)8
Avg EPS beat(12)3.48%
EPS beat(16)10
Avg EPS beat(16)5.05%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.45%
EPS NY rev (1m)0%
EPS NY rev (3m)6.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.43
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS0
BVpS0.49
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -75.48%
ROE -158.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.42%
ROA(5y)-56.3%
ROE(3y)-151.69%
ROE(5y)-107.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.33
Altman-Z -6.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.7%
EPS Next Y11.86%
EPS Next 2Y3.88%
EPS Next 3Y3.29%
EPS Next 5Y17.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.96%
EBIT Next 3Y-17.51%
EBIT Next 5Y-16.24%
FCF growth 1Y-4.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.9%
OCF growth 3YN/A
OCF growth 5YN/A